JAK Inhibitors Have Dupixent In Their Sights For Atopic Dermatitis
Analysts predict that Sanofi and Regeneron's Dupixent is going to dominate the severe eczema market but the oral options of Lilly/Incyte's baricitinib and AbbVie's upadacitinib are progressing through the pipeline to make a challenge.
You may also be interested in...
First Phase III Results Keep Pfizer's Abrocitinib Among JAK Leaders In Atopic Dermatitis
Pfizer follows Lilly as the second company to report positive top-line Phase III results in AD for a JAK inhibitor. Safety is a key concern for the class, but Pfizer did not provide any details about abrocitinib's side effects.
MatriSys Focuses On ‘Good Microbe’ Approach To Dermatology, Maybe Skin Cancer Too
Emerging Company Profile: Calling itself the most advanced microbiome company focused on skin diseases, MatriSys has advanced a proprietary microbe to Phase IIa for atopic dermatitis. The biotech also is eyeing UV-induced cancer, rosacea, acne, psoriasis and bacterial skin infections.
Galderma Cuts Topical Derma R&D In Favor Of Systemic Treatments
Significant shifts in innovation for atopic dermatitis are behind the decision to close down the current R&D center of Nestlé group prescription dermatology business Galderma. The move affects around 550 employees in Sophia Antipolis, France, with only a small proportion likely to be offered jobs in a planned new center of excellence.